Solid Biosciences (NASDAQ:SLDB) Director Sells $46,400.20 in Stock

Solid Biosciences Inc. (NASDAQ:SLDB) Director Ilan Ganot sold 7,205 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $6.44, for a total transaction of $46,400.20. Following the completion of the sale, the director directly owned 25,271 shares of the company’s stock, valued at $162,745.24. This represents a 22.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Ilan Ganot also recently made the following trade(s):

• On Wednesday, January 28th, Ilan Ganot sold 191 shares of Solid Biosciences stock. The shares were sold at an average price of $6.59, for a total transaction of $1,258.69.
• On Monday, January 5th, Ilan Ganot sold 1,053 shares of Solid Biosciences stock. The stock was sold at an average price of $5.43, for a total transaction of $5,717.79.

Solid Biosciences Price Performance

Solid Biosciences stock opened at $6.52 on Monday. Solid Biosciences Inc. has a one year low of $2.41 and a one year high of $7.37. The company’s fifty day moving average price is $5.84 and its two-hundred day moving average price is $5.71. The company has a market capitalization of $507.97 million, a price-to-earnings ratio of -2.62 and a beta of 2.67.

Analysts Set New Price Targets

SLDB has been the subject of several analyst reports. Wall Street Zen lowered Solid Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, October 19th. Chardan Capital reaffirmed a “buy” rating and set a $15.00 price objective on shares of Solid Biosciences in a report on Tuesday, November 4th. JPMorgan Chase & Co. lowered their target price on shares of Solid Biosciences from $13.00 to $11.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Solid Biosciences in a research report on Thursday, January 22nd. Finally, Citigroup restated a “market outperform” rating on shares of Solid Biosciences in a report on Wednesday, December 17th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $14.70.

Institutional Trading of Solid Biosciences

A number of hedge funds have recently bought and sold shares of SLDB. Bollard Group LLC acquired a new stake in Solid Biosciences during the second quarter worth about $1,761,000. Geode Capital Management LLC lifted its position in shares of Solid Biosciences by 184.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,510,153 shares of the company’s stock worth $7,356,000 after acquiring an additional 979,294 shares during the period. Franklin Resources Inc. grew its holdings in shares of Solid Biosciences by 28.9% during the 2nd quarter. Franklin Resources Inc. now owns 1,599,173 shares of the company’s stock worth $7,788,000 after purchasing an additional 358,473 shares in the last quarter. Blair William & Co. IL bought a new stake in shares of Solid Biosciences during the second quarter valued at approximately $807,000. Finally, ProShare Advisors LLC acquired a new position in shares of Solid Biosciences in the second quarter valued at $80,000. 81.46% of the stock is owned by institutional investors.

Solid Biosciences News Roundup

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Company will present at the Guggenheim Emerging Outlook: Biotech Summit (CEO Bo Cumbo presenting Feb 12) — this gives Solid (SLDB) direct exposure to institutional investors and can support a rally if management provides encouraging clinical, regulatory, or financing updates. Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
• Neutral Sentiment: Trading context: SLDB is trading above recent moving averages with volume notably above its average — this suggests heightened interest but does not by itself indicate direction until drivers (presentation vs. insider sales) dominate.
• Negative Sentiment: CEO Alexander (Alex) Cumbo sold 48,913 shares at an average $6.44 (≈$315k); his holding fell ~18.1% — a large CEO sale can be read negatively by investors even if for personal reasons. CEO Sale SEC Filing
• Negative Sentiment: CFO Kevin Tan sold 14,783 shares at $6.44 (~$95k); his position fell ~13.6% — another senior officer reduction that may weigh on sentiment. CFO Sale SEC Filing
• Negative Sentiment: COO David T. Howton sold 18,894 shares at $6.44 (~$122k); ownership declined ~16.2%. COO Sale SEC Filing
• Negative Sentiment: CTO Paul Herzich sold 10,905 shares at $6.44 (~$70k); holding fell ~13.6%. CTO Sale SEC Filing
• Negative Sentiment: Other insiders — director Ilan Ganot (7,205 shares), insider Jessie Hanrahan (12,348 shares), and Gabriel Brooks (12,616 shares) — each sold at $6.44, reducing holdings by double-digit percentages; collectively these sales increase supply pressure and raise investor questions about insider confidence. Director/Insider Sales SEC Filings

About Solid Biosciences

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.